CREATE Medicines
Summary active Updated May 16, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
CREATE Medicines is a Cambridge, MA-based clinical-stage biotechnology company pioneering in vivo immune programming, with a proprietary mRNA-LNP platform that directly engineers T cells, NK cells, and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies 12. The company has dosed more than 50 patients across its in vivo CAR clinical programs, which it describes as the largest dataset in the emerging field 12. The $122M Series B announced May 14, 2026 was co-led by existing investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other current syndicate members; proceeds will advance CRT-402 (CD19-targeted in vivo CAR-T for autoimmune disease) into clinical trials and expand the dual CD19 x BCMA program 12. Ron Philip joined as Executive Chairman; Brian Cuneo (ARCH) and Tom Thomas (Newpath) joined the board 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-05-14 | Series B | $122M | Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners | Alexandria Venture Investments 12 |
What Investors Say
No independently sourced investor quotes found at this time.
What Founders Say
No independently sourced founder quotes found at this time.
Sources
-
PR Newswire, “CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology,” May 14, 2026. Accessed May 2026. https://www.prnewswire.com/news-releases/create-medicines-announces-122-million-series-b-financing-to-advance-in-vivo-car-pipeline-in-autoimmune-disease-and-oncology-302771778.html↩↩↩↩↩
-
BioPharma Dive, “Create Medicines raises $122M to bolster in vivo CAR-T therapies,” May 14, 2026. Accessed May 2026. https://www.biopharmadive.com/news/create-medicines-series-b-in-vivo-car-t-therapy/820226/↩↩↩↩